Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.
Risk & Volatility
Black Diamond Therapeutics has a beta of 3.32, suggesting that its share price is 232% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.
Profitability
This table compares Black Diamond Therapeutics and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Diamond Therapeutics | N/A | -32.10% | -25.21% |
| Xenetic Biosciences | -75.90% | -40.62% | -34.97% |
Analyst Recommendations
This is a summary of recent ratings for Black Diamond Therapeutics and Xenetic Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Diamond Therapeutics | 1 | 2 | 7 | 0 | 2.60 |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
Black Diamond Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 539.53%. Given Black Diamond Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Xenetic Biosciences.
Earnings & Valuation
This table compares Black Diamond Therapeutics and Xenetic Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Diamond Therapeutics | N/A | N/A | $22.37 million | ($0.75) | -2.29 |
| Xenetic Biosciences | $3.26 million | 1.40 | -$2.68 million | ($1.16) | -1.72 |
Black Diamond Therapeutics has higher earnings, but lower revenue than Xenetic Biosciences. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Black Diamond Therapeutics beats Xenetic Biosciences on 11 of the 13 factors compared between the two stocks.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
